Project Team EUnetHTA assessment (PTRCR19)
Project Lead: European Network for Health Technology Assessment (EUnetHTA)
Authors:
1) Mirjana Huic (AIHTA, Austria)
2) Swiss Network for HTA (SNHTA, Switzerland)
Publication: May 2021
Language: German
The clinical evidence for a combination therapy with casirivimab plus imdevimab (REGN-COV2) consists of a published RCT with an adaptive trial design (part of the phase 1/ 2 patient population) with preliminary results in 275 patients with mild-to-moderate SARS-CoV2 disease and the unpublished phase 3 part of the same RCT in 4,567 non-hospitalised high-risk adults with mild-to-moderate SARS-CoV2 disease. Both studies suggest that REGN-COV2 can reduce follow-up treatment, which is particularly relevant for patients at high risk of disease progression, and that REGN-COV2 has a favourable safety profile. However, a final assessment is not possible based on the current data.